Xiaolin Wang

EVP, Clinical Development · 2 filings · Latest: Mar 17, 2026

Revolution Medicines, Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Filing
RVMD	Xiaolin Wang	EVP, Clinical Development	Mar 17, 2026	Sale	$99.48	2,010	$200.0K	116,063	Mar 19 10:53 PM
RVMD	Wang Xiaolin	—	Mar 16, 2026	Proposed Sale	$99.59	2,282	$227.3K	—	Mar 13 11:41 PM